sars-cov-2

Documents about sars-cov-2

• SARS-CoV-2 Pre-exposure Prophylaxis With Ivermectin Retrospective Cohort Study#839288ClinicalTrials.gov
• Monitoring of Anti-SARS-CoV-2 (COVID 19) and Encapsulated Vaccination Patients With Thalassemic and Falcemic Syndromes#850984ClinicalTrials.gov
• FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol#855731ClinicalTrials.gov
• Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Pneumonia#861523ClinicalTrials.gov
• Serological Testing for COVID-19 (SARS-CoV-2) in ESKD#865975ClinicalTrials.gov
• Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test#868418ClinicalTrials.gov
• A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection#841990ClinicalTrials.gov
• Assessment of SARS-CoV-2 lineage alterations and regions of evolutionary variability to detect antigenically altered potential Variants of Interest#26355DataCite
• Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection#201762ClinicalTrials.gov
• Uridine cytidine kinases govern molnupiravir bioactivation and anti-SARS-CoV-2 activity#240425PLOS
• Antibody Response Against SARS-CoV-2 Spike Protein in People with HIV After COVID-19 Vaccination.#281629Repisalud
• Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain#331216Open Research
• Duodenal perforation in a SARS-CoV-2-positive patient with negative PCR results for SARS-CoV-2 in the peritoneal fluid#418054IRIS
• Prevalence of Antibodies Against SARS-CoV-2 Virus That Causes COVID-19 in Tübingen Children#840635ClinicalTrials.gov
• Singapore SARS-CoV-2 Human Challenge Study#843579ClinicalTrials.gov
• Burn Injuries During COVID-19 Pandemic and Its Influence on Length of Stay#847720ClinicalTrials.gov
• Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine#121469ClinicalTrials.gov
• Efficacy and Safety of Oral Lactobacillus Plantarum GUANKE (CGMCC NO.21720) in Enhancement of Antibody Level After SARS-CoV-2 Vaccination (Trial 2)#867317ClinicalTrials.gov
• TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)#882727ClinicalTrials.gov
• SARS-CoV-2 variant-dependent inflammasome activation#291904HAL (France)
• Redundant and distinct mechanisms suppress innate immune activation during SARS-CoV-2 infection#209848PLOS
• Electrophysiological Impact of SARS-CoV-2 Envelope Protein in U251 Human Glioblastoma Cells: Possible Implications in Gliomagenesis?#330435IRIS
• The SARS-CoV-2 S2′-helix compared to stem-helix confers higher genetic barrier to antibody resistance#428186PLOS
• Strategic Planning of a Joint SARS-CoV-2 and Influenza Vaccination Campaign in the UK#648522Spiral
• COVID19-hematological Malignancies: the Italian Hematology Alliance#834692ClinicalTrials.gov
• Phase 2b/3 Trial of VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine.#861737ClinicalTrials.gov
• Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel#871338ClinicalTrials.gov
• Accurate Detection of SARS-CoV-2 by Next-Generation Sequencing in Low Viral Load Specimens#213130HAL (France)
• Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate#824994ClinicalTrials.gov
• Identifying Risks of COVID-19 Outbreaks in Work Settings and the Implications for Control Measures#855019ClinicalTrials.gov
• Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2#848630ClinicalTrials.gov
• Low Dose Radiation Therapy for Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2), COVID-19#869030ClinicalTrials.gov
• Multiple Mechanisms of Action of Sulfodyne®, a Natural Antioxidant, against Pathogenic Effects of SARS-CoV-2 Infection#202594HAL (France)
• VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection#836682ClinicalTrials.gov
• Depression, Anxiety and SARS-CoV-2 (Covid-19) Phobia in Post-stroke Patients#843208ClinicalTrials.gov
• The Influence of SARS-CoV-2 Lifestyle Changes on Non-alcoholic Fatty Liver Disease Evolution#861558ClinicalTrials.gov
• Using Vibroacoustic Therapy in a Patient With Co-infection and COVID-19#865629ClinicalTrials.gov
• SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations#181593ClinicalTrials.gov
• Variations in the expression and function of SARS-CoV-2 entry molecules induced by exposure to nano- and microparticles#250680Kyoto University Research Information Repository
• Variations in the expression and function of SARS-CoV-2 entry molecules induced by exposure to nano- and microparticles#250690Kyoto University Research Information Repository
• Serological Response to SARS-Cov-2 Virus in Personnel of the Institut Bergonié in the Context of the COVID-19 Pandemic#842498ClinicalTrials.gov
• ACE2-PNA conjugates exploit viral endocytosis for targeted intracellular delivery and exhibit dual antiviral efficacy against SARS-CoV-2#651869Europe PMC
• Efficacy and Safety of Ozonised Oil (HOO) in COVID-19 Patients#871752ClinicalTrials.gov
• Knowledge and Practices of Mask Usage During the COVID-19 Pandemic#276119RCAAP
• Repurposing screens reveal a role for PKCη and NF1 in SARS-CoV-2 infection#396690PLOS
• Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a#832748ClinicalTrials.gov
• Safety and Immunogenicity of NVX-CoV2705#272430ClinicalTrials.gov
• Efficacy and Safety of NVX-CoV2705#283095ClinicalTrials.gov
• PEP Flute-selfcare in COVID-19#373628ClinicalTrials.gov
• HTRF-based identification of small molecules targeting SARS-CoV-2 E protein interaction with ZO-1 PDZ2#395333HAL (France)